The CDC recommends vaccination for adults age 60 and up. “We have vaccines and they are very effective.”įor infants, immunization consists of a monoclonal antibody and for older adults, two vaccines are available. People most susceptible to RSV “can get vaccinated against RSV,” Amiji says. This year, for the first time ever, immunization against RSV is available for both older adults and babies entering their first RSV season. Last year, COVID-19 infections ran into an early flu season and an unusual surge of respiratory infections in young children to create what some experts called a “tripledemic.”Ī common respiratory infection that most children get by the age of 2, RSV is particularly dangerous for premature infants, babies younger than 6 months and children with health issues according to the CDC, which says RSV hospitalizes about 58,000 children under 5 years old every year in the U.S. The updated vaccine targets XBB.1.5, nicknamed Kraken. The effectiveness of the new COVID-19 vaccine against HV.1 is unknown at this time, but health experts expect it to provide coverage since HV.1 is part of the Omicron family whose subvariant, XBB.1.5 was circulating this spring. Symptoms include cough, fatigue, runny nose and congestion. Health experts say that while HV.1 is highly contagious, it appears to be relatively mild. Hospitalization rates for COVID-19 are low in all states except West Virginia and Hawaii, where the Centers for Disease Control and Prevention says they are medium.Ī variant called HV.1 is currently the most prevalent subvariant of COVID in the U.S., accounting for 29% of cases and surpassing Eris (EG.5), the dominant strain this summer. We’re in a very different place with COVID compared to where we were even a year ago and definitely compared to two years ago,” Maniar says. “This is the sort of new normal that we will be in for the foreseeable future. We have the right tools,” says Neil Maniar, a professor of public health practice at Northeastern. “I think we’re in a new place with COVID in the sense that we have effective vaccines and a clear vaccination schedule. “In terms of virulence, we’ve seen a decline.” “But the good news in both cases, especially for those who have been fully vaccinated, is that even if they get the infection, it will be fairly mild,” Amiji says. Photos by Matthew Modoono/Northeastern University (From left to right): Mansoor Amiji, university distinguished professor of pharmaceutical sciences and chemical engineering, and Neil Maniar, a professor of public health practice in the Bouvé College of Health Sciences, predict vaccination and natural immunity will make for a mild COVID season this winter. ![]() ![]() “As we go toward the holiday season and we gather to celebrate different events and as the temperature starts to drop, it’s inevitable we’re going to see a spike in respiratory infections such as flu and COVID,” he says. So even if you get a COVID infection, you should have a milder reaction,” says Mansoor Amiji, university distinguished professor of pharmaceutical sciences and chemical engineering. “We know that the majority of Americans have been vaccinated against COVID or had a natural infection or both. ![]() The COVID-19 winter forecast is for relatively mild illness thanks to vaccination and natural immunity, health experts at Northeastern University say.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |